Abstract: SA-PO0482
GLP-1 Receptor Agonist Use and Patient-Reported Physical Function in CKD
Session Information
- CKM: Clinical - Screening, Population Management, Care Disparities, and Patient-Centered Outcomes
October 24, 2026 | Location: Exhibit Hall A, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Cardiovascular-Kidney-Metabolic Health
- 602 Cardiovascular-Kidney-Metabolic Health: Clinical
Authors
- Sontz, Ethan J., Northeast Ohio Medical University College of Medicine, Rootstown, Ohio, United States
- Shafiabadi Hassani, Neda, UH Cleveland Medical Center, Cleveland, Ohio, United States
- Padiyar, Aparna, UH Cleveland Medical Center, Cleveland, Ohio, United States
- Rajagopalan, Sanjay, UH Cleveland Medical Center, Cleveland, Ohio, United States
- Neeland, Ian J., UH Cleveland Medical Center, Cleveland, Ohio, United States
- Dobre, Mirela A., UH Cleveland Medical Center, Cleveland, Ohio, United States
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used in chronic kidney disease (CKD), but associated weight loss has raised concerns regarding frailty, sarcopenia, fatigue, and physical functioning. We evaluated whether GLP-1RA therapy was associated with changes in patient-reported physical functioning and quality of life in CKD.
Methods
We conducted a prospective observational study of CKD stage 2 participants enrolled in the UH CINEMA cardiometabolic program who completed the physical functioning questions of the SF-36 questionnaire to evaluate limitations in physical activities, energy/fatigue, and overall health perception. The questionnaire was applied at baseline (n=138) and repeated after 3 months (currently n=25). Outcomes were compared according to GLP-1RA use >1 year (n=71) versus no prior GLP-1RA exposure (n=67) at baseline and again after 3 months.
Results
Mean age was 61± 8 and mean eGFR 78 mL/min/1.73m^2. Baseline scores were similar between groups by GLP-1RA use. After 3 months follow-up, no significant worsening in physical functioning, energy/fatigue, or overall health perception was observed among GLP-1RA-treated participants. In contrast, GLP-1RA therapy was associated with directional improvements in overall health perception (p=0.05) and energy/fatigue (p=0.06), with modest favorable trends across several physical functioning domains. No meaningful longitudinal changes were observed in participants not receiving GLP-1RA therapy.
Conclusion
In patients with mild CKD and high cardiometabolic risk, GLP-1RA therapy was not associated with worsening patient-reported physical functioning or quality-of-life measures over 1 year and may be associated with modest improvements in selected domains. Further studies with larger sample sizes and objective functional assessments are warranted.